Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

L. Taramasso, P. Tatarelli, E. Ricci, G. Madeddu, B. Menzaghi, N. Squillace, G.V. De Socio, C. Martinelli, R. Gulminetti, P. Maggi, G. Orofino, F. Vichi, A. Di Biagio, P. Bonfanti, C. Bellacosa, L. Calza, C. Abeli, B.M. Celesia, C. Grosso, A. StagnoF. Mazzotta, G. Penco, G. Cassola, L.A. Nicolini, C. Dentone, C. Molteni, L. Palvarini, A. Scalzini, L. Carenzi, G. Rizzardini, L. Valsecchi, L. Cordier, S. Rusconi, V. Colombo, M. Galli, M. Franzetti, A. Sgrelli, E. Mazzotta, G. Parruti, P. Bagella, M.S. Mura, R. Libertone, A. Antinori, S. Di Giambenedetto, M. Guastavigna, P. Caramello

Research output: Contribution to journalArticle

Cite this

Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., De Socio, G. V., Martinelli, C., Gulminetti, R., Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, P., Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., ... Caramello, P. (2018). Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). BMC Infectious Diseases, 18(1), 357. https://doi.org/10.1186/s12879-018-3268-5